Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open-Label, Multi-Center Study of PDS0101 and Pembrolizumab (KEYTRUDA) Combination Immunotherapy in Subjects With Recurrent and/or Metastatic HNSCC and High-Risk HPV16 Infection

Next Previous
X
Search
Trial Profile

A Phase II, Open-Label, Multi-Center Study of PDS0101 and Pembrolizumab (KEYTRUDA) Combination Immunotherapy in Subjects With Recurrent and/or Metastatic HNSCC and High-Risk HPV16 Infection

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PDS 0101 (Primary) ; Pembrolizumab (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms VERSATILE-002
  • Sponsors PDS Biotechnology Corporation

    • Most Recent Events

    • 03 May 2024 According to a PDS Biotechnology Corporation media release, company announced virtual Key Opinion Leader (KOL) event to be held on Wednesday, May 8, 2024, which will focus on the positive, updated data from this clinical trial.
    • 23 Apr 2024 According to a PDS Biotechnology Corporation media release, the company announced a Key Opinion Leader Event to discuss positive, updated data from its VERSATILE-002 Phase 2 clinical trial with Versamune in combination with pembrolizumab and next steps for Versamune HPV and PDS01ADC.
    • 24 Oct 2023 Results (n=18) of an analysis assessing cytokines and chemokines associated with a predominant effector, stimulatory functional profile presented at the 48th European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top